Literature DB >> 25838437

Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding?

Ronald K Binder1, Thomas F Lüscher2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838437     DOI： 10.1093/eurheartj/ehv103

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  9 in total

Review 1.  Nanotechnology in diagnosis and treatment of coronary artery disease.

Authors:  Mahdi Karimi; Hossein Zare; Amirala Bakhshian Nik; Narges Yazdani; Mohammad Hamrang; Elmira Mohamed; Parham Sahandi Zangabad; Seyed Masoud Moosavi Basri; Leila Bakhtiari; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2016-02-23       Impact factor: 5.307

2.  The effect of cessation of 2nd generation P2Y12 inhibitor therapy on platelet reactivity in patients 1 year after acute myocardial infarction.

Authors:  Guy Witberg; Jalal Bathish; Tamir Bental; Dorit Leshem-Lev; Abid Assali; Ran Kornowski; Eli Lev
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

3.  Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.

Authors:  Minghuan Jiang; Joyce H S You
Journal:  Clin Cardiol       Date:  2017-07-06       Impact factor: 2.882

4.  Application of Feedback System Control Optimization Technique in Combined Use of Dual Antiplatelet Therapy and Herbal Medicines.

Authors:  Wang Liu; Yu-Long Li; Mu-Ting Feng; Yu-Wei Zhao; Xianting Ding; Ben He; Xuan Liu
Journal:  Front Physiol       Date:  2018-05-04       Impact factor: 4.566

5.  Efficacy and safety of short-term (≤6 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials.

Authors:  Chun Lin Xiang; Yi Zhen Gong; Long Jia Zeng; Bei Bei Luo; Jian Xu; Yan He
Journal:  Anatol J Cardiol       Date:  2016-11-10       Impact factor: 1.596

6.  Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease.

Authors:  Guy Witberg; Ygal Plakht; Tamir Bental; Becca S Feldman; Maya Leventer-Roberts; Amos Levi; Hagit Gabay; Ran Balicer; Yariv Gerber; Ran Kornowski
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

7.  Very very late stent thrombosis: 9.5 years after DES implantation.

Authors:  Sanjiv Gupta
Journal:  Indian Heart J       Date:  2016-02-11

Review 8.  Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease.

Authors:  Navdeep K Bhatti; Keyvan Karimi Galougahi; Yehuda Paz; Tamim Nazif; Jeffrey W Moses; Martin B Leon; Gregg W Stone; Ajay J Kirtane; Dimitri Karmpaliotis; Sabahat Bokhari; Mark A Hardy; Geoffrey Dube; Sumit Mohan; Lloyd E Ratner; David J Cohen; Ziad A Ali
Journal:  J Am Heart Assoc       Date:  2016-08-04       Impact factor: 5.501

Review 9.  Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome : Practical lessons from a review.

Authors:  J M Ten Berg; B Zwart; A W J van 't Hof; A Liem; J Waltenberger; R J de Winter; J W Jukema
Journal:  Neth Heart J       Date:  2017-12       Impact factor: 2.380
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.